Cellular Biomedicine Group to Report Second Quarter 2019 Results on August 6, 2019

NEW YORK and SHANGHAI, July 23, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. CBMG ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the second quarter ended June 30, 2019 after the market closes on Tuesday, August 6, 2019.

The Company will host a conference call and webcast with the investment community on Tuesday, August 6^th at 4:30 p.m. Eastern Time / Wednesday, August 7^th at 4:30 a.m. China Standard Time featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG.

About Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. It conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. Its GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and U.S. GMP standards. 

For more information, please contact:

Company Contact:

Derrick C. Li

Head of Strategy and Investor Relations, CBMG

Phone: 917-717-0994

Email: derrick.li@cellbiomedgroup.com

Investor Contact:

Valter Pinto / Allison Soss

KCSA Strategic Communications

Phone: 212-896-1254 / 212-896-1267

Email: cellbiomed@kcsa.com   

View original content:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-to-report-second-quarter-2019-results-on-august-6-2019-300889382.html

SOURCE Cellular Biomedicine Group